We have the
history
to change the
future
Explore our timeline of Frontline AIDS' 30-year history of
partnership and innovation
A future
free from AIDS
for everyone,
everywhere
A future
free from AIDS
for everyone,
everywhere
Our focus
areas
Our global advocacy galvanises urgent action on HIV prevention.
We advocate for health care that focuses on the whole person, not just on individual health issues.
We support communities to fight for human rights and promote justice, holding perpetrators, institutions and governments to account by using evidence.
We design and generate evidence about what does and doesn’t work and share what we learn.
We support our partners to strengthen the community systems that are essential to the HIV response, the climate crisis, and future pandemics.
We support adolescents and young people, especially young women with HIV, to lead programmes and reach their full potential as leaders and advocates.
Where
we work
The Frontline AIDS partnership is made up of 60 partners spanning 100 countries. We work in places most affected by HIV and in countries with emerging epidemics.
explore
News and
Blogs
View all
Frontline AIDS welcomes Gilead’s announcement to allow six generic manufacturers to sell its potentially game-changing HIV prevention drug, lenacapavir, while recognising that the treatment remains unaffordable to many.
This year, researchers unveiled major interim results from two Phase 3 trials of injectable lenacapavir (LEN-LA). This new long-acting injectable, administered just once every six months, has been shown to outperform daily oral PrEP options, marking another significant breakthrough in the field of HIV prevention. Given LEN-LA's effectiveness, what needs to happen for it to reach those most in need?
